Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: To compare rates of and risk factors for hospitalizations among Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) participants taking metformin and randomly assigned to insulin glargine U-100, glimepiride, liraglutide, or sitagliptin.

Research Design And Methods: Intention-to-treat (ITT) (N = 5,047) and on-assigned-treatment (AT) (N = 4,830) data sets were used. Baseline differences between those hospitalized versus those not hospitalized were assessed. Kaplan-Meier analysis was used to determine incidence for time to first hospitalization, and log-rank tests were used to determine treatment group differences. Time-to-event analyses were used to examine factors affecting subsequent hospitalization risk.

Results: During GRADE, 1,636 participants (32.4%) were hospitalized at least once and 751 (14.9%) were hospitalized more than once. Hospitalized participants were older, less likely to be Hispanic, more likely to be White, and more likely to have a history of hypertension and had higher baseline BMI. There were no treatment group differences in incidence for time to first hospitalization in the ITT data set (P = 0.148), but a reduced hazard rate was observed for those taking liraglutide versus those taking glimepiride in the AT data set (hazard ratio 0.78 [95% CI 0.66, 0.92]; P = 0.022). Factors increasing the risk for subsequent hospitalizations included meeting the secondary outcome (HbA1c >7.5%, confirmed), each prior hospitalization, and change from assigned treatment (29%, 41%, and 56% increase in risk, respectively). Assignment to liraglutide versus glimepiride reduced this risk by 13%.

Conclusions: Hospitalizations were common in GRADE, and rates were nearly identical across treatment groups. The small, but significant, reduction in risk for subsequent hospitalizations among participants assigned to liraglutide versus glimepiride may influence treatment decisions in populations similar to GRADE participants.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12178615PMC
http://dx.doi.org/10.2337/dc24-2839DOI Listing

Publication Analysis

Top Keywords

liraglutide versus
12
versus glimepiride
12
grade participants
8
incidence time
8
time hospitalization
8
treatment group
8
group differences
8
data set
8
risk subsequent
8
subsequent hospitalizations
8

Similar Publications

Aims: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide cardiovascular and renal benefits in type 2 diabetes, but their real-world effects in individuals with obesity without diabetes are unclear. This study aimed to evaluate the cardiovascular and kidney outcomes of GLP-1RAs versus other anti-obesity medications (AOMs) in adults with obesity.

Materials And Methods: This target trial emulation used TriNetX electronic health records (July 2021-May 2025) to identify adults with obesity and no diabetes history who initiated GLP-1RAs (liraglutide, semaglutide, or tirzepatide) or other AOMs.

View Article and Find Full Text PDF

Purpose: Overweight or obese women with polycystic ovary syndrome (PCOS) often experience significant metabolic and hormonal disturbances. This systematic review and meta-analysis evaluated whether liraglutide combined with metformin is more effective than metformin alone in improving glycaemic control, lipid metabolism, body mass index (BMI) and sex hormone profiles in this population.

Methods: We systematically searched PubMed, EMBASE, the Cochrane Library, China National Knowledge Infrastructure, Weipu, SinoMed and Wanfang Data for randomised controlled trials (RCTs) comparing liraglutide plus metformin to metformin monotherapy in overweight or obese women with PCOS.

View Article and Find Full Text PDF

Objective: To inform clinical decision-making for patients with obesity, binge eating disorder (BED) and bipolar disorder (BD), we compared individuals with BED and those without BED who participated in a randomised controlled trial (RCT) of liraglutide for weight loss in stable BD with obesity.

Methods: This was a post hoc analysis of a published, 40-week, placebo-controlled, double-blind trial of liraglutide in 60 participants with stable BD and obesity or overweight. Participants with BED were compared to those without BED regarding demographics, psychiatric and medical comorbidity, BD treatment, and response to liraglutide versus placebo.

View Article and Find Full Text PDF

Purpose: Tirzepatide, a dual GLP-1/GIP agonist, shows promise for weight loss, but its safety compared to GLP-1 receptor agonists requires (liraglutide, semaglutide) clarification for clinical decision-making. This systematic review evaluates their safety profiles in patients with obesity or overweight.

Methods: We conducted a PRISMA-compliant systematic review (PROSPERO: CRD42024576314) of RCTs from PubMed, Embase, and Cochrane (inception to August 20, 2024).

View Article and Find Full Text PDF

Recent cardiovascular outcome trials (CVOTs) have reshaped the therapeutic landscape of type 2 diabetes mellitus (T2DM), revealing that certain glucose-lowering agents, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), offer substantial cardiovascular benefits beyond glycemic control. Injectable GLP-1RAs, such as semaglutide and liraglutide, have been shown to reduce major adverse cardiovascular events (MACE), but barriers, including cost, access, and the burden of injections, persist. The SOUL trial marks a significant milestone by evaluating oral semaglutide in high-risk patients, demonstrating a 14% reduction in MACE versus placebo and reinforcing GLP-1RAs cardioprotective potential in an oral formulation.

View Article and Find Full Text PDF